AR064493A1 - ISOQUINOLIN AND ISOQUINOLINONA SUBSTITUTED DERIVATIVES - Google Patents

ISOQUINOLIN AND ISOQUINOLINONA SUBSTITUTED DERIVATIVES

Info

Publication number
AR064493A1
AR064493A1 ARP070105858A ARP070105858A AR064493A1 AR 064493 A1 AR064493 A1 AR 064493A1 AR P070105858 A ARP070105858 A AR P070105858A AR P070105858 A ARP070105858 A AR P070105858A AR 064493 A1 AR064493 A1 AR 064493A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
aryl
heterocyclyl
halogen
Prior art date
Application number
ARP070105858A
Other languages
Spanish (es)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR064493A1 publication Critical patent/AR064493A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)

Abstract

utiles para el tratamiento y/o prevencion de enfermedades asociadas con la Rhoquinasa y/o la fosforilacion mediada por la Rho-quinasa de la fosfatasa de la cadena ligera de miosina, y a composiciones que contienen dichos compuestos. Reivindicacion 1: Un compuesto de la formula (1)en la que R1 es H, OH o NH2, R2 es R', alquilo C7-8, alquileno C1-6-R', alquenilo C2-6, alquinilo C2-6, alquileno C1-6-O-R', alquileno C1-6-CH[R']2, alquileno C1-6-C(O)-R', alquileno C1-6-C(O)NH2, alquileno C1-6- C(O)NH-R' alquileno C1-6-C(O)NH-alquilo C1-6, alquileno C1-6-C(O)N[alquilo C1-6]2, alquileno C1-6-C(O)N[R']2; alquileno C1-6-C(O)O-alquilo C1-6, C(O)O-alquilo C1-6, C(O)OR', C(O)-alquilo C1-6, C(O)R', C(O)NH-alquilo C1-6, C(O)NHR', C(O)-NH-alquenilo C2-6, C(O)-NH-alquinilo C2-6, C(O)-NH-alquileno C1-6-R', C(O)N[alquil C1-6]R', C(O)N[alquilo C1-6]2, C(O)-alquileno C1-6-R', C(O)O-alquileno C1-6-R'; o R2 es alquilo C1-6, con la condicion de que en dicho resto alquilo al menos un H esta sustituido con OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONH2, CONHCH3 o CON(CH3)2; o R2 es un alquileno C1-4 unido a la amina cíclica, donde el alquileno C1-4 forma un segundo enlace con un átomo e carbono diferente de la amina cíclica y forma, junto con átomos e C de la amina cíclica, un segundo anillo de 4-8 miembros; R3 es H, halogeno, alquilo C1-6, alquileno C1-6-R', OH, O-Rö, NH2, NHRö, NRöRö o NH-C(O)tRö, R4 es H, halogeno, hidroxi, CN, alquilo C1-6, R', alquileno C1-6-R'; R5 es H, halogeno, CN, NO2, alquilo C1-6, alquenilo C2-6, R', alquileno C1-6-arilo C6-10, alquenileno C1-6-arilo C6-10, alquileno C1-6-heterociclilo C5-10, CH(OH)-alquilo C1-6, NH2, NH-R', NH-SO2H, NH-SO2-alquiIo C1-6, NH-SO2-R', NH-C(O)-alquilo C1-6, NH-C(O)-R', C(O)N[alquilo C1-6]2, C(O)OH, o C(O)O-alquilo C1-6; R6 es H, R', alquilo C1-8, alquileno C1-6-R', alquileno C1-6-O-alquilo C1-6, alquileno C1-6-O-R', alquileno C1-6-CH[R']2, alquileno C1-6-C(O)-R', alquileno C1-6-C(O)NH2, alquileno C1-6-C(O)NH-R', alquileno C1-6-C(O)NH-alquilo C1-6, alquileno C1-6-C(O)N[alquilo C1-6]2, alquileno C1-6-C(O)N[R']2, alquileno C1-6-C(O)O-alquilo C1-6, C(O)O-alquilo C1-6, C(O)OR', C(O)-alquilo C1-6, C(O)R', C(O)NH-alquilo C1-6, C(O)NHR', C(O)N[alquil C1-6]R', C(O)N[alquilo C1-6]2, C(O)-alquileno C1-6-R', C(O)O-alquileno C1-6-R', R7 es H, halogeno, CN, NO2, alquilo C1-6, O-alquilo C1-6, alquenilo C2-6, R', alquenileno C1-6-arilo C6-10, alquileno C1-6-R', CH(OH)-alquilo C1-6, NH2, NH-R', NH-SO2H, NH-SO2- alquilo C1-6, NH-SO2-R', SO2-NH2, SO2-NHR', NH-C(O)-alquilo C1-6, NH-C(O)-R', C(O)N[alquilo C1-6]2, C(O)OH, o C(O)O-alquilo C1-6; R8 es H, halogeno o alquilo C1-6; n es 1,2, 3 o 4; m es 1, 2, 3, 4 o 5; y L es O(CH2)p, S(CH2)p, S(O)(CH2)p, S(O)(CH2)p, SO2(CH2)p, NH(CH2)p, N-alquil C1-6-(CH2)p, N-cicloalquil C3-6-(CH2)p, N[CO-alquil C1-6]-(CH2)p o N[alquileno C1-3)-R']-(CH2)p; p es 0, 1, 2, 3 o 4; donde R' es cicloalquilo C3-8, heterociclilo C5-10, arilo C6-10; Rö es cicloalquilo C3-8, heterociclo C5-10, arilo C6-10, alquilo C1-6, alquileno C1-6-R', alquileno C1-6-O-alquilo C1-6, alquileno C1-6-O-R', o alquileno C1-6-NRxRy; y donde Rx, y Ry son independientemente entre sí alquilo C1-6, heterociclilo C5-10, arilo C6-10, alquileno C1-4-heterociclilo C5-10, alquileno C1-4-arilo C6-10, alquileno C1-4-NH-alquilo C1-6, alquileno C1-4-NH[alquilo C1-6]2, alquileno C1-4-N[arilo C6-10]2, o alquileno C1-4-N[heterociclilo C5-10]2; donde en los restos R2, R4, R5, R6, R7 y R8, el grupo alquilo, alquileno o cicloalquilo pueden estar opcionalmente sustituidos una o más veces con OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONH2, CONHCH3 o CON(CH3)2; donde en los restos R2 a R8, el alquilo o alquileno puede estar opcionalmente sustituido una o más veces con halogeno; donde en los restos R2 a R8, los grupos arilo C6-10 y heterociclilo C5-10 están sin sustituir o sustituidos una o más veces con grupos adecuados seleccionados independientemente entre halogeno, OH, NO2, N3, CN, C(O)-alquilo C1-6, C(O)-arilo C1-6, COOH, COO-alquilo C1-6, CONH2, CONH-alquilo C1-6, CON[alquilo C1-6]2, cicloalquilo C3-8, alquilo C1-6, alquileno C1-6-OH, alquileno C1-6-NH2, alquileno C1-6-NH-alquilo C1-6, alquileno C1-6-N[alquilo C1-6]2, alquenilo C2-6, alquinilo C2-6, O-alquilo C1-6, O-C(O)-alquilo C1-6, PO3H2, SO3H, SO2-NH2, SO2NH-alquilo C1-6, SO2N[alquilo C1-6]2, y S-alquilo C1-6; SO-alquilo C1-6, SO2-alquilo C1-6, SO2-N=CH-N[alquiIo C1-6]2, C(NH)(NH2), NH2, NH-alquilo C1-6, N[aIquiIo C1-6]2, NH-C(O)-alquilo C1-6), NH-C(O)O-alquilo C1-6, NH-SO2-alquilo C1-6, NH-SO2-arilo C6-10, NH-SO2-heterociclilo C5-10, N-alquil C1-6-C(O)-alquilo C1-6, N-alquil C1-6-C(O)O-alquilo C1-6, N-alquil C1-6-C(O)-NH-alquilo C1-6], arilo C6-10, alquileno C1-6-arilo C6-10, O-arilo C6-10, O-alquileno C1-6-arilo C6-10, heterociclilo C5-10, alquiIeno C1-6-heterociclilo C5-10, u O-alquileno C1-6-heterociclilo C5-10, donde el grupo arilo C6-10 o heterociclilo C5-10 puede estar sustituido de una a tres veces con un grupo seleccionado independientemente entre halogeno, OH, NO2, CN, O-alquilo C1-6, alquilo C1-6, NH2, NH-alquilo C1-6, N[alquilo C1-6]2, SO2CH3, COOH, C(O)O-alquilo C1-6, CONH2, alquileno C1-6-O-aIquilo C1-6, alquileno C1-6-O- arilo C6-10, u O-alquileno C1-6-arilo C6-10; o donde el grupo arilo C6-10 está sustituido vecinalmente con un grupo O-alquileno C1-4-O, por lo que se forma, junto con los átomos de carbono a los que están unidos los átomos de oxígeno, un anillo de 5- 8 miembros. y donde los sustituyentes arilo o heterociclilo de los grupos arilo C6-10 y heterociclilo C5-10 no pueden estar adicionalmente sustituidos con un grupo que contiene arilo o heterociclilo; y o sus formas estereoisoméricas y/o tautoméricas y/o sus sales farmacéuticamente aceptables.useful for the treatment and / or prevention of diseases associated with Rhokinase and / or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing said compounds. Claim 1: A compound of the formula (1) wherein R1 is H, OH or NH2, R2 is R ', C7-8 alkyl, C1-6-R alkylene, C2-6 alkenyl, C2-6 alkynyl, C1-6-O-R 'alkylene, C1-6-CH [R'] 2 alkylene, C1-6-C (O) -R 'alkylene, C1-6-C alkylene (O) NH2, C1-6 alkylene - C (O) NH-R 'C1-6-C alkylene (O) NH-C1-6 alkyl, C1-6-C alkylene (O) N [C1-6 alkyl] 2, C1-6-C alkylene ( O) N [R '] 2; C1-6-C (O) alkylene O-C1-6 alkyl, C (O) O-C1-6 alkyl, C (O) OR ', C (O) -C 1-6 alkyl, C (O) R' , C (O) NH-C1-6 alkyl, C (O) NHR ', C (O) -NH-C2-6 alkenyl, C (O) -NH-C2-6 alkynyl, C (O) -NH- C1-6-R 'alkylene, C (O) N [C1-6 alkyl] R', C (O) N [C1-6 alkyl] 2, C (O) -C 1-6-R-alkylene, C ( O) C1-6-R 'alkylene; or R2 is C1-6 alkyl, with the proviso that in said moiety alkyl at least one H is substituted with OH, OCH3, COOH, COOCH3, NH2, NHCH3, N (CH3) 2, CONH2, CONHCH3 or CON (CH3) 2; or R2 is a C1-4 alkylene attached to the cyclic amine, where C1-4 alkylene forms a second bond with a carbon atom different from the cyclic amine and forms, together with C atoms of the cyclic amine, a second ring 4-8 members; R3 is H, halogen, C1-6 alkyl, C1-6-R 'alkylene, OH, O-Rö, NH2, NHRö, NRöRö or NH-C (O) tRö, R4 is H, halogen, hydroxy, CN, alkyl C1-6, R ', C1-6-R' alkylene; R5 is H, halogen, CN, NO2, C1-6 alkyl, C2-6 alkenyl, R ', C1-6 alkylene-C6-10 aryl, C1-6 alkenylene C6-10 aryl, C1-6 alkylene-C5 heterocyclyl -10, CH (OH) -C1-6 alkyl, NH2, NH-R ', NH-SO2H, NH-SO2-C1-6 alkyl, NH-SO2-R', NH-C (O) -C1 alkyl 6, NH-C (O) -R ', C (O) N [C1-6 alkyl] 2, C (O) OH, or C (O) O-C1-6 alkyl; R6 is H, R ', C1-8 alkyl, C1-6-R alkylene, C1-6-O-C1-6 alkyl, C1-6-O-R' alkylene, C1-6-CH alkylene [R '] 2, C1-6-C alkylene (O) -R', C1-6-C alkylene (O) NH2, C1-6-C alkylene (O) NH-R ', C1-6-C alkylene (O ) NH-C1-6 alkyl, C1-6-C alkylene (O) N [C1-6 alkyl] 2, C1-6-C alkylene (O) N [R '] 2, C1-6-C alkylene (O ) O-C1-6 alkyl, C (O) O-C1-6 alkyl, C (O) OR ', C (O) -C 1-6 alkyl, C (O) R', C (O) NH-alkyl C1-6, C (O) NHR ', C (O) N [C1-6 alkyl] R', C (O) N [C1-6 alkyl] 2, C (O) -C 1-6-R alkylene , C (O) O-C1-6-R 'alkylene, R7 is H, halogen, CN, NO2, C1-6 alkyl, O-C1-6 alkyl, C2-6 alkenyl, R', C1-6 alkenylene C6-10 aryl, C1-6-R 'alkylene, CH (OH) -C1-6 alkyl, NH2, NH-R', NH-SO2H, NH-SO2- C1-6 alkyl, NH-SO2-R ', SO2-NH2, SO2-NHR ', NH-C (O) -C 1-6 alkyl, NH-C (O) -R', C (O) N [C1-6 alkyl] 2, C (O) OH, or C (O) O-C1-6 alkyl; R8 is H, halogen or C1-6 alkyl; n is 1,2, 3 or 4; m is 1, 2, 3, 4 or 5; and L is O (CH2) p, S (CH2) p, S (O) (CH2) p, S (O) (CH2) p, SO2 (CH2) p, NH (CH2) p, N-C1-alkyl 6- (CH2) p, N3-6- (CH2) cycloalkyl p, N [CO- C1-6 alkyl] - (CH2) by N [C1-3 alkylene) -R '] - (CH2) p; p is 0, 1, 2, 3 or 4; where R 'is C3-8 cycloalkyl, C5-10 heterocyclyl, C6-10 aryl; Rö is C3-8 cycloalkyl, C5-10 heterocycle, C6-10 aryl, C1-6 alkyl, C1-6-R alkylene, C1-6-O-C1-6 alkyl, C1-6-O-R alkylene ', or C1-6-NRxRy alkylene; and where Rx, and Ry are independently from each other C1-6 alkyl, C5-10 heterocyclyl, C6-10 aryl, C1-4 alkylene-C5-10 heterocyclyl, C1-4 alkylene-C6-10 aryl, C1-4 alkylene NH-C1-6 alkyl, C1-4 alkylene-NH [C1-6 alkyl] 2, C1-4-N alkylene [C6-10 aryl] 2, or C1-4-N alkylene [C5-10 heterocyclyl] 2; where in the radicals R2, R4, R5, R6, R7 and R8, the alkyl, alkylene or cycloalkyl group may be optionally substituted one or more times with OH, OCH3, COOH, COOCH3, NH2, NHCH3, N (CH3) 2, CONH2, CONHCH3 or CON (CH3) 2; where in the R2 through R8 moieties, the alkyl or alkylene may be optionally substituted one or more times with halogen; where at radicals R2 through R8, the C6-10 aryl and C5-10 heterocyclyl groups are unsubstituted or substituted one or more times with suitable groups independently selected from halogen, OH, NO2, N3, CN, C (O) -alkyl C1-6, C (O) -C 1-6 aryl, COOH, COO-C 1-6 alkyl, CONH2, CONH-C 1-6 alkyl, CON [C 1-6 alkyl] 2, C3-8 cycloalkyl, C 1-6 alkyl , C1-6-OH alkylene, C1-6-NH2 alkylene, C1-6-NH-C1-6 alkyl, C1-6-N alkylene [C1-6 alkyl] 2, C2-6 alkenyl, C2-6 alkynyl , O-C1-6 alkyl, OC (O) -C1-6 alkyl, PO3H2, SO3H, SO2-NH2, SO2NH-C1-6 alkyl, SO2N [C1-6 alkyl] 2, and S-C1-6 alkyl; SO-C1-6 alkyl, SO2-C1-6 alkyl, SO2-N = CH-N [C1-6 alkyl] 2, C (NH) (NH2), NH2, NH-C1-6 alkyl, N [C1 aIquIo -6] 2, NH-C (O) -C 1-6 alkyl), NH-C (O) O-C1-6 alkyl, NH-SO2-C1-6 alkyl, NH-SO2-C6-10 aryl, NH -SO2-C5-10 heterocyclyl, N-C1-6-C-alkyl (O) -C1-6 alkyl, N-C1-6-C alkyl (O) O-C1-6 alkyl, N-C1-6 alkyl- C (O) -NH-C1-6 alkyl], C6-10 aryl, C1-6 alkylene-C6-10 aryl, O-C6-10 aryl, O- C 1-6 alkylene-C6-10 aryl, C5- heterocyclyl 10, C1-6 alkylene C5-10 heterocyclyl, or O-C 1-10 alkylene-C5-10 heterocyclyl, wherein the C6-10 aryl group or C5-10 heterocyclyl can be substituted one to three times with an independently selected group between halogen, OH, NO2, CN, O-C1-6 alkyl, C1-6 alkyl, NH2, NH-C1-6 alkyl, N [C1-6 alkyl] 2, SO2CH3, COOH, C (O) O-alkyl C1-6, CONH2, C1-6-O-aC1-6 alkyl, C1-6-O-aryl C6-10, or O-C1-6 alkylene-C6-10 aryl; or where the C6-10 aryl group is substituted neighborhoodly with a C1-4-O-alkylene group, so that, together with the carbon atoms to which the oxygen atoms are attached, a 5- ring is formed 8 members and where the aryl or heterocyclyl substituents of the C6-10 aryl and C5-10 heterocyclyl groups cannot be further substituted with an aryl or heterocyclyl-containing group; and or its stereoisomeric and / or tautomeric forms and / or its pharmaceutically acceptable salts.

ARP070105858A 2006-12-27 2007-12-21 ISOQUINOLIN AND ISOQUINOLINONA SUBSTITUTED DERIVATIVES AR064493A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026892 2006-12-27

Publications (1)

Publication Number Publication Date
AR064493A1 true AR064493A1 (en) 2009-04-08

Family

ID=38015325

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105858A AR064493A1 (en) 2006-12-27 2007-12-21 ISOQUINOLIN AND ISOQUINOLINONA SUBSTITUTED DERIVATIVES

Country Status (30)

Country Link
US (1) US8772492B2 (en)
EP (1) EP2132194B1 (en)
JP (1) JP5313919B2 (en)
KR (1) KR101545533B1 (en)
CN (1) CN101573354B (en)
AR (1) AR064493A1 (en)
AT (1) ATE502027T1 (en)
AU (1) AU2007338411B2 (en)
BR (1) BRPI0720909A2 (en)
CA (1) CA2673921C (en)
CL (1) CL2007003819A1 (en)
CO (1) CO6210690A2 (en)
CR (1) CR10815A (en)
DE (1) DE602007013295D1 (en)
DK (1) DK2132194T3 (en)
EC (1) ECSP099469A (en)
ES (1) ES2363105T3 (en)
IL (1) IL199538A (en)
MA (1) MA31024B1 (en)
MX (1) MX2009005862A (en)
MY (1) MY148902A (en)
NI (1) NI200900109A (en)
NO (1) NO20092434L (en)
PT (1) PT2132194E (en)
RU (1) RU2009128690A (en)
SV (1) SV2009003316A (en)
TN (1) TN2009000273A1 (en)
TW (1) TWI448286B (en)
WO (1) WO2008077555A2 (en)
ZA (1) ZA200903554B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101213187B (en) 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 Isoquinoline derivatives as inhibitors of RHO-kinase
US7470787B2 (en) 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
KR101373535B1 (en) 2005-07-26 2014-03-12 사노피 Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors
WO2007012422A1 (en) 2005-07-26 2007-02-01 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
EP2068878B1 (en) 2006-09-20 2019-04-10 Aerie Pharmaceuticals, Inc. Rho kinase inhibitors
JP5405314B2 (en) 2006-12-27 2014-02-05 サノフイ Cycloalkylamine substituted isoquinolone derivatives
JP5318779B2 (en) 2006-12-27 2013-10-16 サノフイ Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
RU2009128690A (en) 2006-12-27 2011-02-10 Санофи-Авентис (Fr) NEW SUBSTITUTED DERIVATIVES OF Isoquinoline and Isoquinolinone
AU2007338408B2 (en) 2006-12-27 2012-07-26 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
MX2009005825A (en) 2006-12-27 2009-06-16 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase.
CA2673920C (en) 2006-12-27 2015-03-24 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8524737B2 (en) * 2008-06-24 2013-09-03 Sanofi Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
SI2303846T1 (en) 2008-06-24 2015-08-31 Sanofi Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
PL2313374T3 (en) 2008-06-24 2014-03-31 Sanofi Sa 6-substituted isoquinolines and isoquinolinones
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010045580A1 (en) * 2008-10-17 2010-04-22 Exelixis, Inc. Sphingosine-1-phosphate receptor antagonists
CA2929545C (en) 2009-05-01 2019-04-09 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
RU2012119488A (en) * 2009-10-13 2013-11-20 Мсд Осс Б.В. CONDENSED ASINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ACETHYLCHOLINE RECEPTOR
HUE027309T2 (en) * 2011-07-08 2016-10-28 Sanofi Sa Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
CN102993178A (en) * 2012-12-04 2013-03-27 天津红日药业股份有限公司 Isoquinoline compound with Rho kinase inhibition activity and preparation method and application thereof
JP6576325B2 (en) * 2013-03-15 2019-09-18 セルジーン シーエーアール エルエルシー Heteroaryl compounds and their use
NZ711376A (en) 2013-03-15 2020-01-31 Sanofi Sa Heteroaryl compounds and uses thereof
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN109528721B (en) 2013-03-15 2021-10-01 爱瑞制药公司 Combination therapy
JP6729963B2 (en) 2014-01-31 2020-07-29 株式会社エーピーアイ コーポレーション Pipecolic acid 4-position hydroxylase and method for producing 4-hydroxyamino acid using the same
FR3017868A1 (en) 2014-02-21 2015-08-28 Servier Lab ISOQUINOLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2017057730A1 (en) 2015-10-02 2017-04-06 株式会社エーピーアイ コーポレーション Method for producing hydroxy-l-pipecolic acid
JP6832946B2 (en) 2015-11-17 2021-02-24 アエリエ ファーマシューティカルズ インコーポレイテッド How to prepare kinase inhibitors and their intermediates
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
JP6907319B2 (en) 2016-08-31 2021-07-21 アエリエ ファーマシューティカルズ インコーポレイテッド Ophthalmic composition
AU2018243687C1 (en) 2017-03-31 2020-12-24 Alcon Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020056345A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (en) 1977-04-13 1986-05-16 Anvar DIPYRIDO (4,3-B) (3,4-F) INDOLES, PROCESS FOR OBTAINING IT, THERAPEUTIC APPLICATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1992002476A1 (en) 1990-07-31 1992-02-20 E.I. Du Pont De Nemours And Company Catalytic equilibration of selected halocarbons
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
CZ301044B6 (en) 1996-08-12 2009-10-21 Mitsubishi Tanabe Pharma Medicaments comprising Rho kinase inhibiting amide derivatives
JPH1087629A (en) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd New isoquinoline derivative, and its medicinal use
AU8872198A (en) 1997-08-29 1999-03-22 Zeneca Limited Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
ATE327230T1 (en) 2000-01-20 2006-06-15 Eisai Co Ltd PIPERIDINE COMPOUNDS AND MEDICATIONS CONTAINING SAME
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US20040171533A1 (en) 2000-02-29 2004-09-02 Barbara Zehentner Methods and compositions for regulating adiopocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (en) 2000-04-08 2003-12-26 Astrazeneca Ab PIPERIDINE DERIVATIVES, PROCESS FOR THE PREPARATION AND USE OF THESE DERIVATIVES IN THE MANUFACTURE OF MEDICINES
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
WO2002034712A1 (en) 2000-10-27 2002-05-02 Takeda Chemical Industries, Ltd. Process for preparing substituted aromatic compounds and intermediates therefor
EP1351936A1 (en) 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0101038D0 (en) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
JP2004534017A (en) 2001-04-27 2004-11-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド BACE inhibitors
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma Rho KINASE INHIBITORS
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (en) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
AU2003281623B8 (en) * 2002-07-22 2009-06-11 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
JPWO2004024717A1 (en) * 2002-09-12 2006-01-05 麒麟麦酒株式会社 Isoquinoline derivative having kinase inhibitory activity and medicament containing the same
US20040266755A1 (en) 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
US20070021404A1 (en) 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1667979A4 (en) 2003-09-23 2007-04-18 Merck & Co Inc Isoquinoline potassium channel inhibitors
US7723352B2 (en) 2003-09-23 2010-05-25 Merck Sharp & Dohme Isoquinolinone potassium channel inhibitors
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
WO2005035516A1 (en) 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
EP1689719A1 (en) 2003-11-25 2006-08-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
JP2005232175A (en) * 2004-01-21 2005-09-02 Asahi Kasei Pharma Kk 5-substituted isoquinoline as medicine
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
EP1729761A4 (en) 2004-03-05 2008-09-03 Eisai Co Ltd Cadasil treatment with cholinesterase inhibitors
SE0400850D0 (en) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
CN101213187B (en) * 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 Isoquinoline derivatives as inhibitors of RHO-kinase
KR101373535B1 (en) 2005-07-26 2014-03-12 사노피 Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors
WO2007012422A1 (en) 2005-07-26 2007-02-01 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
TW200745101A (en) * 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
RU2009128690A (en) 2006-12-27 2011-02-10 Санофи-Авентис (Fr) NEW SUBSTITUTED DERIVATIVES OF Isoquinoline and Isoquinolinone
JP5318779B2 (en) 2006-12-27 2013-10-16 サノフイ Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives

Also Published As

Publication number Publication date
TWI448286B (en) 2014-08-11
JP5313919B2 (en) 2013-10-09
WO2008077555A3 (en) 2009-05-07
DE602007013295D1 (en) 2011-04-28
BRPI0720909A2 (en) 2016-11-01
CR10815A (en) 2009-08-12
CA2673921C (en) 2015-10-20
ES2363105T3 (en) 2011-07-20
TN2009000273A1 (en) 2010-10-18
CL2007003819A1 (en) 2008-08-01
PT2132194E (en) 2011-05-16
MY148902A (en) 2013-06-14
KR20090094109A (en) 2009-09-03
NI200900109A (en) 2010-01-15
AU2007338411A1 (en) 2008-07-03
AU2007338411B2 (en) 2012-08-23
TW200843771A (en) 2008-11-16
EP2132194A2 (en) 2009-12-16
IL199538A (en) 2013-11-28
JP2010514720A (en) 2010-05-06
CA2673921A1 (en) 2008-07-03
ECSP099469A (en) 2009-07-31
NO20092434L (en) 2009-09-23
CO6210690A2 (en) 2010-10-20
CN101573354B (en) 2014-02-12
US8772492B2 (en) 2014-07-08
WO2008077555A2 (en) 2008-07-03
ATE502027T1 (en) 2011-04-15
DK2132194T3 (en) 2011-06-27
RU2009128690A (en) 2011-02-10
EP2132194B1 (en) 2011-03-16
ZA200903554B (en) 2010-05-26
CN101573354A (en) 2009-11-04
SV2009003316A (en) 2010-02-05
MA31024B1 (en) 2009-12-01
US20100056566A1 (en) 2010-03-04
MX2009005862A (en) 2009-06-17
KR101545533B1 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
AR064493A1 (en) ISOQUINOLIN AND ISOQUINOLINONA SUBSTITUTED DERIVATIVES
AR064531A1 (en) DERIVATIVES OF ISOQUINOLIN AND ISOQUINOLINONA SUBSTITUTED WITH CYCLLOKYLAMINE AND ITS USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF RHO-KINASE
AR064492A1 (en) ISOQUINOLONE DERIVATIVES SUBSTITUTED WITH CICLOALQUILAMINA
AR064533A1 (en) DERIVATIVES OF ISOQUINOLIN AND ISOQUINOLINONA SUBSTITUTED AND ITS USE IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES RELATED TO THE INHIBITION OF RHO-QUINASA.
AR072281A1 (en) ISOQUINOLINAS AND ISOQUINOLINONAS REPLACED
AR057082A1 (en) CICLOHEXILAMINISOQUINOLONA DERIVATIVES
AR054518A1 (en) ISOQUINOLINE DERIVATIVES
AR075475A1 (en) USEFUL HIPEROCICLIC DERIVATIVES OF PIPERAZINE AS HERBICITY AGENTS AND PROCESS TO COMBAT THE GROWTH OF INDESEATED PLANTS.
AR054868A1 (en) ISOQUINOLONE DERIVATIVES REPLACED WITH PIPERIDINYL
AR086538A1 (en) COMPOUNDS TO REDUCE THE PRODUCTION OF B-AMYLOID
AR040477A1 (en) HETEROCICLICALLY SUBSTITUTED BENZOILUREAS, PROCEDURE FOR PREPARATION AND USE AS PHARMACOS
AR050610A1 (en) DIHYDROPTERIDINONE DERIVATIVES
CO5680403A2 (en) MCHR1R ANTAGONISTS
AR039222A1 (en) DERIVATIVES OF QUINOLINE AND ISOQUINOLINE, A METHOD FOR THEIR PREPARATION AND ITS USE AS INFLAMMATION INHIBITORS
AR056265A1 (en) N-AMINOMETILENSULPHONAMIDES REPLACED, ITS PREPARATION AND ITS USE AS MEDICINES
AR049098A1 (en) PIRIMIDINE DERIVATIVES THAT ARE ANTAGONISTS OF THE VITRONECTINE RECEPTOR. PROCEDURE FOR OBTAINING AND PHARMACEUTICAL COMPOSITIONS
AR050611A1 (en) DERIVATIVES OF DIHYDRIPTERIDINONE
DOP2010000046A (en) SUBSTITUTED BICYCOLACTAMA COMPOUNDS
CO5640152A2 (en) PHARMACEUTICAL COMPOSITIONS FOR INHIBITORS OF THE PROTEASE OF THE VIRUS OF HEPATITIS C
ES2330313T3 (en) THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST INFECTION WITH FLAVIVIRUS.
AR056986A1 (en) AZA HETEROCICLOS AS INHIBITORS OF KINASES. PROCEDURE FOR OBTAINING AND PHARMACEUTICAL COMPOSITIONS
AR067757A1 (en) IMIDAZO DERIVATIVES [4,5-C] PIRIDIN-2-ONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME AS ANTIVIRAL AGENTS.
AR079448A1 (en) INHIBITORS OF SPINING KINASE
CO6180439A2 (en) DERIVATIVES OF QUINUCLIDINOL AS ANTAGONISTS OF MUSCARINIC RECEPTORS
AR033678A1 (en) DERIVATIVES OF QUINOLINA, PROCEDURE TO PREPARE THEM, USE OF THE SAME FOR THE PREPARATION OF MEDICINES AND THE MEDICINES CONTAINING THESE DERIVATIVES

Legal Events

Date Code Title Description
FB Suspension of granting procedure